ERBB2 and neoplasm: Indeed, in 29% (14/48) of TN breast tumours BRCA1 promoter was hypermethylated compared to 5% (3/57) of HR-positive/HER2-negative and 2% (1/50) of HER2-positive tumours (Table 1).